Winstrol (Stanozolol) 100mg/ml 10 ml Medical Pharma Steroids in USA

C21H32N2O = 328.5.
CAS — 10418-03-8.
ATC — A14AA02.
ATC Vet — QA14AA02.

NOTE. The following terms have been used as ‘street names’ or slang names for various forms of stanozolol: Iron Brew.

Pharmacopoeias. In China and US.

USP 31(Stanozolol). An odourless crystalline powder occurring in 2 forms; needles melt at about 155°and prisms at about 235°.
Insoluble in water; soluble 1 in 41 of alcohol, 1 in 74 of chloroform, and 1 in 370 of ether; slightly soluble in acetone and in ethyl acetate; soluble in dimethylformamide; very slightly soluble in benzene. Store in airtight containers. Protect from light.

Winstrol contains: 100mg

100 mg / ml Stanozolol

Pharmacologic category

Androgen.

Dosing: Adult

100mg, once every week.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Androgens are usually avoided in children with hereditary angioedema (below) because of their adverse effects, but they have been used when other treatments are ineffective. In the USA oral doses of stanozolol 1 mg daily, given only during an attack, have been used in children under 6 years of age, and up to 2 mg daily in those aged 6 to 12 years.

Slightly higher doses have been permitted in children in the UK.

Has not been used in the injected form in the pediatric population.

Dosing: Renal impairment

No dosage adjustment provided in manufacturer’s labeling; use with caution due to propensity to cause edema.

Dosing: Hepatic impairment

No dosage adjustment provided in manufacturer’s labeling; use with caution.

Use

Stanozolol has anabolic and androgenic properties, with other anabolic steroids, stanozolol has been used for breast cancer in postmenopausal women, and for anaemias, osteoporosis, and catabolic disorders. It has been given in oral doses of 2 mg every 8 to 12 hours, or 50 mg by intramuscular injection every 2 or 3 weeks.

In the management of hereditary angioedema, an initial oral dose of 2.5 to 10 mg daily has been given to prevent attacks. The dosage may then be reduced, according to the patient’s response; maintenance doses of 2 mg daily or on alternate days, or 2.5 mg three times weekly have been used successfully. For doses that have been used in children, see below.

Stanozolol raises serum concentrations of C1 esterase inhibitor and has been used successfully to prevent attacks of hereditary angioedema.

Stanozolol has been used in the treatment of vascular manifestations of Behçet’s syndrome. It has also been reported to promote fibrinolysis in vascular disorders, and has been tried in various conditions. However, most studies have been non-comparative and in small numbers of patients, and results have been variable.

Storage/Stability

Store in a dark, dry place at room temperature.

Contraindications

Hypersensitivity to stanozolol or any component of the formulation.

Men with carcinomas of the breast or with known or suspected carcinomas of the prostate; women who are or may become pregnant.

Documentation of allergenic cross-reactivity for androgens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Gynecomastia: May cause Gynecomastia.

Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis or liver cell tumors, which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests.

Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected.

Disease related concerns:

Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis.
Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.

Hepatic impairment: Use with caution in patients with hepatic impairment.

Pregnancy risk factor

X

Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Pregnancy considerations

Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.

Lactation

Excretion in breast milk unknown/not recommended

Breast feeding considerations

It is not known if stanozolol is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.

Adverse reactions

As for androgens and anabolic steroids in general. As with other 17α-alkylated compounds stanozolol may produce hepatotoxicity, and liver function should be monitored. It is probably best avoided in patients with hepatic impairment, and certainly if this is severe. Haematocrit and haemoglobin concentrations should also be monitored.

Because of its androgenic effects it has been recommended that stanozolol should not be used to treat hereditary angioedema in premenopausal women except in life-threatening situations.

Effects on the kidney. Renal failure with cholestatic jaundice has been reported with Stanozolol.

Effects on the liver. Cholestatic jaundice has been reported with stanozolol, in some cases with acute tubular necrosis and renal failure.

Effects on the nervous system. Benign intracranial hypertension developed in an elderly woman receiving stanozolol; CSF pressure returned to normal after stanozolol was stopped.

Porphyria. Stanozolol is considered to be unsafe in patients with porphyria because it has been shown to be porphyrinogenic in animals.

Frequency unknown.

Cardiovascular: Edema.

Central nervous system: Depression, excitation, insomnia.

Dermatologic: Acne (females and prepubertal males).

Also reported in females: Hirsutism, male-pattern baldness.

Endocrine & metabolic: Electrolyte imbalances, glucose intolerance, gonadotropin secretion inhibited, gynecomastia, HDL decreased, LDL increased, libido changes.

Also reported in females: Clitoral enlargement, menstrual irregularities.

Genitourinary:

Prepubertal males: Increased or persistent erections, penile enlargement
Postpubertal males: Bladder irritation, epididymitis, impotence, oligospermia, priapism (chronic), testicular atrophy, testicular function inhibited

Hematologic: Prothrombin time increased, suppression of clotting factors.

Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, cholestatic jaundice, hepatic necrosis (rare), hepatocellular neoplasms, peliosis hepatis (with long-term therapy).

Neuromuscular & skeletal: CPK increased, premature closure of epiphyses (in children).

Renal: Creatinine excretion increased.

Metabolism/Transport effects

None known.

Drug interactions

Corticosteroids, Warfarin and Antidiabetic agents.

Test interactions

May suppress factors II, V, VII, and X; may increase PT; may decrease thyroxine-binding globulin and radioactive iodine uptake.

Monitoring parameters

Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy.

Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation).

Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer.

Dosage forms

Injectable form 50mg/ml and 100mg/ml.

Anatomic Therapeutic Chemical (ATC) Classification

A14AA02.

Mechanism of action

Anabolic steroid derived from dihydrotestosterone (DHT) sharing similar properties, allegedly having much more anabolic potency with less androgenic effects. Also it is known for having a much longer half-life with less protein binding affinity than DHT.

Pharmacodynamics/Kinetics

Stanozolol can be detected up to 20 days in blood, half-life is estimated to be around 7 days but can vary widely depending on route of administration (oral, intramuscular), even with the same route, highly variable absorption between subjects (human and animals) has been a common problem.

Metabolism: hepatic

Elimination: renal

Buy anabolic steroids online in USA.